Episodes
Wednesday Nov 09, 2022
The Human Data Era - The Role of Human Diversity in Progressing Precision Medicine
Wednesday Nov 09, 2022
Wednesday Nov 09, 2022
By understanding disease risk through the information found in a person’s genome, scientists can develop more effective therapeutics and clinicians can treat their patients more effectively.
In this episode, we talk to Kári Stefánsson, founder and CEO of deCODE Genetics, a Reykjavik-based biopharmaceutical company that collects and analyzes genealogical, medical, and genomic data at a national scale in order to identify variants that cause disease. We discuss his pioneering work in population-scale genetics, its applications in precision medicine and the healthcare system, and the difficult questions that access to these data raise.
To dive further into this topic, please join Amgen scientists at the Human Data Era Q&A webinar discussion on November 16, 2022. Register for the event here.
Welcome to The Human Data Era, a special edition podcast series produced by The Scientist’s Creative Services Team.
This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
By studying human genetics, scientists discovered mechanisms that, when defective, cause disease. While this type of data is powerful, additional information can provide more insight on the human condition. Researchers and clinicians can now go beyond genetics, combining proteomics, metabolomics, transcriptomics, and environmental factors into a broad category of human data. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, explores the potential of human data and the important transition scientists and clinicians are making to incorporate this wealth of information into drug research and development.
Wednesday Nov 02, 2022
The Human Data Era - Exploring Human Data in Cardiovascular Disease
Wednesday Nov 02, 2022
Wednesday Nov 02, 2022
Heterogeneous disorders such as cardiovascular disease have multiple risk factors, causes, and manifestations. Having a holistic view of a patient’s unique biology potentially leads to earlier and better treatment options.
In this episode, we talk to Narimon Honarpour, vice president of Global Development at Amgen, about how human data is helping drug developers and clinicians unpack the complexities of cardiovascular disease to improve patient outcomes.
To dive further into this topic, please join Amgen scientists at the Human Data Era Q&A webinar discussion on November 16, 2022. Register for the event here.
Welcome to The Human Data Era, a special edition podcast series produced by The Scientist’s Creative Services Team.
This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
By studying human genetics, scientists discovered mechanisms that, when defective, cause disease. While this type of data is powerful, additional information can provide more insight on the human condition. Researchers and clinicians can now go beyond genetics, combining proteomics, metabolomics, transcriptomics, and environmental factors into a broad category of human data. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, explores the potential of human data and the important transition scientists and clinicians are making to incorporate this wealth of information into drug research and development.
Wednesday Oct 26, 2022
The Human Data Era - New Connections Between Genetics and Human Disease
Wednesday Oct 26, 2022
Wednesday Oct 26, 2022
Biobanks that house data from electronic health records or collect samples directly from participants are precious resources for researchers looking to understand health and disease and translate these discoveries into recommendations and treatments for patients.
In this episode, we talk to Nancy Cox, professor and director of the Vanderbilt Genetics Institute, about Vanderbilt’s DNA biobank, BioVU. Nancy and her fellow researchers use computational genetics to study the de-identified patient DNA stored in the bank along with corresponding electronic health records in order to discover links between genes and disease.
To dive further into this topic, please join Amgen scientists at the Human Data Era Q&A webinar discussion on November 16, 2022. Register for the event here.
Welcome to The Human Data Era, a special edition podcast series produced by The Scientist’s Creative Services Team.
This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
By studying human genetics, scientists discovered mechanisms that, when defective, cause disease. While this type of data is powerful, additional information can provide more insight on the human condition. Researchers and clinicians can now go beyond genetics, combining proteomics, metabolomics, transcriptomics, and environmental factors into a broad category of human data. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, explores the potential of human data and the important transition scientists and clinicians are making to incorporate this wealth of information into drug research and development.
Wednesday Oct 19, 2022
The Human Data Era - Human Data: Beyond the Genome
Wednesday Oct 19, 2022
Wednesday Oct 19, 2022
Welcome to The Human Data Era, a special edition podcast series produced by The Scientist’s Creative Services Team.
This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
By studying human genetics, scientists discovered mechanisms that, when defective, cause disease. While this type of data is powerful, additional information can provide more insight on the human condition. Researchers and clinicians can now go beyond genetics, combining proteomics, metabolomics, transcriptomics, and environmental factors into a broad category of human data. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, explores the potential of human data and the important transition scientists and clinicians are making to incorporate this wealth of information into drug research and development.
With a whole host of patient data at our fingertips, drug developers are becoming more thoughtful and strategic in developing medicines and designing clinical trials to test them. In this episode we talk to Rob Lenz, Senior Vice President of Global Development at Amgen. We review the full scope of human data, going beyond the genome to explore the challenges of using human data as well as the opportunities of applying human data to drug research and clinical trials.
To dive further into this topic, please join Amgen scientists at the Human Data Era Q&A webinar discussion on November 16, 2022. Register for the event here.
Wednesday Oct 19, 2022
Exposed: Environmental Echoes in Health - How Toxins Leave Their Cancerous Marks
Wednesday Oct 19, 2022
Wednesday Oct 19, 2022
Through epigenetic mechanisms, some environmental toxicants, such as heavy metals, reversibly alter gene expression patterns that then drive cancer progression. In this episode, Yvonne Fondufe-Mittendorf discusses her work studying environmental toxicants and their effects on DNA methylation and chromatin structure.
Welcome to Exposed: Environmental Echoes in Health, a special edition podcast series produced by The Scientist’s Creative Services Team. This series is brought to you by Van Andel Institute, an independent biomedical research institute devoted to improving human health for generations to come.
While the human body’s cells all use the same set of instructions, they can end up with wildly different features and functions. Beyond the information stored in DNA, factors within a person’s environment, including chemicals, microbes, and their diet, change how cells work. In this series, Niki Spahich from The Scientist’s Creative Services Team talks to researchers from Van Andel Institute who investigate how the environment and behavior change cellular functions through epigenetic processes.
Wednesday Oct 12, 2022
Exposed: Environmental Echoes in Health - Are We What Our Parents Eat?
Wednesday Oct 12, 2022
Wednesday Oct 12, 2022
Substances that enter the body, such as food or chemicals, can make epigenetic changes in the germline that become inherited, affecting the health of future generations. In this episode, Heidi Lempradl discusses her work studying the effects of parental diet on their offspring.
Welcome to Exposed: Environmental Echoes in Health, a special edition podcast series produced by The Scientist’s Creative Services Team. This series is brought to you by Van Andel Institute, an independent biomedical research institute devoted to improving human health for generations to come.
While the human body’s cells all use the same set of instructions, they can end up with wildly different features and functions. Beyond the information stored in DNA, factors within a person’s environment, including chemicals, microbes, and their diet, change how cells work. In this series, Niki Spahich from The Scientist’s Creative Services Team talks to researchers from Van Andel Institute who investigate how the environment and behavior change cellular functions through epigenetic processes.
Wednesday Oct 05, 2022
Exposed: Environmental Echoes in Health - Epigeneticist Turned Microbe Hunter
Wednesday Oct 05, 2022
Wednesday Oct 05, 2022
Welcome to Exposed: Environmental Echoes in Health, a special edition podcast series produced by The Scientist’s Creative Services Team. This series is brought to you by Van Andel Institute, an independent biomedical research institute devoted to improving human health for generations to come.
While the human body’s cells all use the same set of instructions, they can end up with wildly different features and functions. Beyond the information stored in DNA, factors within a person’s environment, including chemicals, microbes, and their diet, change how cells work. In this series, Niki Spahich from The Scientist’s Creative Services Team talks to researchers from Van Andel Institute who investigate how the environment and behavior change cellular functions through epigenetic processes.
Microbes surround us, and they can have surprising effects beyond infection. In this episode, Nick Burton discusses his work discovering new environmental bacteria in backyards and how exposure to both bad or good bugs can affect an organism’s offspring.
Wednesday Sep 28, 2022
The New Era of Neurodegeneration Research
Wednesday Sep 28, 2022
Wednesday Sep 28, 2022
The brain’s intractable nature makes neurodegenerative disorders challenging to study, but modern assays and technologies give scientists a fresh look at this complex organ. In this episode, Niki Spahich from The Scientist’s Creative Services Team spoke with Erdem Gültekin Tamgüney, a professor in the Institute of Physical Biology at Heinrich Heine University Dusseldorf, about technologies driving modern neuroscience research and his own work exploring the link between ischemic stroke and Parkinson’s disease.
LabTalk is a special edition podcast produced by The Scientist's Creative Services Team, where we explore topics at the leading edge of innovative research. This month’s episode is sponsored by PerkinElmer.
Wednesday Sep 21, 2022
Innovating Clinical Trials: Real-World Clinical Trial Design and Execution in Oncology
Wednesday Sep 21, 2022
Wednesday Sep 21, 2022
Cancer is one therapeutic area where patients cannot wait the conventional 10 or 12 years for a new therapy. For these patients, time is of the essence, and improved access to faster clinical trials can be the difference between receiving a new life-saving medicine and it being too late.
In this episode, we talk to David Raben, vice president of Global Development Oncology at Amgen, about the next generation of oncology trial design and execution.
To dive further into this topic, please join Amgen scientists at the Innovating Clinical Trials Q&A webinar discussion on September 28, 2022. Register for the event here.
Welcome to Innovating Clinical Trials, a special edition podcast series produced by The Scientist’s Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
Clinical trials are desperate for innovation. Speed and efficiency need to improve as many patients cannot wait over a decade for new, potentially lifesaving medicines, and trial participants often do not reflect the patient population. Because clinical trials are complex and multidisciplinary, there is not a single, simple solution for accelerating progress. In this series, Rob Lenz, senior vice president of Global Development at Amgen, explores the latest approaches in clinical trial design and execution and highlights real-world examples of how scientists can run trials better and faster to develop optimal medicines that benefit patients.
Wednesday Sep 14, 2022
Innovating Clinical Trials: The Right Patients
Wednesday Sep 14, 2022
Wednesday Sep 14, 2022
With advances in genetics and other human data, researchers and doctors will one day be able to practice precision medicine. However, predicting how a patient will respond to a medicine is challenging in under-represented patients who are often not included in clinical trials. This is due in part to systemic issues that deter people from participating in research, especially those who have been historically excluded due to factors such as race, ethnicity, sex, and age.
In this episode, we talk to Ponda Motsepe-Ditshego, vice president and Global Medical Therapeutic Area head in General Medicine at Amgen, about the recognized differences in disease incidence among racial and ethnic groups and new approaches to increase representation in clinical trials.
To dive further into this topic, please join Amgen scientists at the Innovating Clinical Trials Q&A webinar discussion on September 28, 2022. Register for the event here.
Welcome to Innovating Clinical Trials, a special edition podcast series produced by The Scientist’s Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
Clinical trials are desperate for innovation. Speed and efficiency need to improve as many patients cannot wait over a decade for new, potentially lifesaving medicines, and trial participants often do not reflect the patient population. Because clinical trials are complex and multidisciplinary, there is not a single, simple solution for accelerating progress. In this series, Rob Lenz, senior vice president of Global Development at Amgen, explores the latest approaches in clinical trial design and execution and highlights real-world examples of how scientists can run trials better and faster to develop optimal medicines that benefit patients.